Earnings Per Share |
Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share (“EPS”) for the three and nine months ended September 30, 2024 and 2023:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
|
|
|
|
(dollars in thousands, except share and per share amounts) |
Numerator |
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to common stockholders |
$ |
11,110 |
|
|
$ |
8,596 |
|
|
$ |
14,185 |
|
|
$ |
16,761 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator |
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding - basic |
36,279,056 |
|
|
38,336,100 |
|
|
36,252,957 |
|
|
39,402,507 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive effect of warrants |
— |
|
|
— |
|
|
3,586 |
|
|
— |
|
|
|
|
|
Dilutive effect of options |
112,487 |
|
|
— |
|
|
115,251 |
|
|
— |
|
|
|
|
|
Dilutive effect of share-based awards |
105,794 |
|
|
104,292 |
|
|
176,974 |
|
|
146,528 |
|
|
|
|
|
Weighted average common shares outstanding - diluted |
36,497,337 |
|
|
38,440,392 |
|
|
36,548,768 |
|
|
39,549,035 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share |
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ |
0.31 |
|
|
$ |
0.22 |
|
|
$ |
0.39 |
|
|
$ |
0.43 |
|
|
|
|
|
Diluted |
$ |
0.30 |
|
|
$ |
0.22 |
|
|
$ |
0.39 |
|
|
$ |
0.42 |
|
|
|
|
|
The Company excluded 1.8 million and 0.2 million common stock equivalents from diluted EPS related to antidilutive equity instruments during the three and nine months ended September 30, 2024, respectively. For the three months ended September 30, 2024, the antidilutive effect is primarily attributable to the warrants. During the three months ended September 30, 2024, the average stock price of the Company was below the strike price of the warrants, whereas during the nine months ended September 30, 2024, the average stock price exceeded the warrants’ strike price. The Company excluded 2.0 million and 2.2 million common stock equivalents from diluted EPS related to antidilutive equity instruments during the three and nine months ended September 30, 2023, respectively
|